SOURCE: WayPoint Biomedical, Inc.

September 29, 2005 16:15 ET

WayPoint Currently in Negotiations to Acquire Two Industry Related Medical Companies

HUNTINGTON BEACH - CA -- (MARKET WIRE) -- September 29, 2005 -- WayPoint Biomedical, Inc. (OTC: WYPB) has entered into negotiations with two different industry-related medical product firms. With the successful completion of these transactions, WayPoint's projected revenues could increase by more than ten fold.

WayPoint CEO, Dennis Shepherd, comments, "Both of these companies have patent protected, revolutionary new products, which could provide WayPoint with a decided advantage over the competition in these multi-million dollar markets. If either one or both of these transactions are completed, WayPoint will further continue to generate additional shareholder value, and be ahead of its goals by at least one year." Mr. Shepherd adds, "We believe this move will further enhance investor confidence and increase shareholder value, which is an integral component of WayPoint's overall goals. Considering these potential acquisition opportunities, innovative new product launches and a previous release announcing a 300% increase in revenues, we believe our stock is much undervalued."

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. The Company's primary target sectors are the Over the Counter (OTC) Self-Testing Market, the Diagnostic Point of Care (POC) Testing Market, and the Homeland Security & Defense Market; three of the fastest growing areas in all of diagnostic medicine and science. For more information on WayPoint Biomedical visit www.waypointbiomedical.com, www.drinkdetectiveusa.com.

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information